Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (411-420 of 688) with videos related to

Pageof 69
Sort By:
American Journal of Nephrology|March 31, 2026
Effect of finerenone treatment discontinuation on kidney and cardiovascular outcomes: a FIDELITY analysisAjay K Singh, Stefan D Anker, Bertram Pitt, et al.
Pharmacological Research|December 4, 2018
Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT studyGiuseppe Derosa, Pamela Maffioli, Laura Scelsi, et al.
European Journal of Heart Failure|February 3, 2016
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF studyKen Lee Chin, Timothy J Collier, Bertram Pitt, et al.
European Journal of Heart Failure|July 4, 2015
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)Jane A Cannon, Timothy J Collier, Li Shen, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|April 10, 2016
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH SubstudyMichael A Weber, Michael Bloch, George L Bakris, et al.
Journal of Cardiac Failure|March 25, 2018
Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT TrialAkshay S Desai, Jiankang Liu, Marc A Pfeffer, et al.
European Heart Journal|July 30, 2025
Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fractionMasatake Kobayashi, Antoni Bayes-Genis, Kevin Duarte, et al.
European Journal of Heart Failure|November 18, 2017
Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trialSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
Journal of the American College of Cardiology|November 1, 2023
Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1cRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
Journal of the American College of Cardiology|February 16, 2018
Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial FibrillationJoão Pedro Ferreira, Nicolas Girerd, John Gregson, et al.
Pageof 69

Showing results (411-420 of 688) with videos related to

Sort By:
Pageof 69
American Journal of Nephrology|March 31, 2026
Effect of finerenone treatment discontinuation on kidney and cardiovascular outcomes: a FIDELITY analysisAjay K Singh, Stefan D Anker, Bertram Pitt, et al.
Pharmacological Research|December 4, 2018
Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT studyGiuseppe Derosa, Pamela Maffioli, Laura Scelsi, et al.
European Journal of Heart Failure|February 3, 2016
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF studyKen Lee Chin, Timothy J Collier, Bertram Pitt, et al.
European Journal of Heart Failure|July 4, 2015
Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)Jane A Cannon, Timothy J Collier, Li Shen, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|April 10, 2016
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH SubstudyMichael A Weber, Michael Bloch, George L Bakris, et al.
Journal of Cardiac Failure|March 25, 2018
Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT TrialAkshay S Desai, Jiankang Liu, Marc A Pfeffer, et al.
European Heart Journal|July 30, 2025
Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fractionMasatake Kobayashi, Antoni Bayes-Genis, Kevin Duarte, et al.
European Journal of Heart Failure|November 18, 2017
Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trialSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
Journal of the American College of Cardiology|November 1, 2023
Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1cRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
Journal of the American College of Cardiology|February 16, 2018
Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial FibrillationJoão Pedro Ferreira, Nicolas Girerd, John Gregson, et al.
Pageof 69